KMT2A and acute myeloid leukemia: Consistent with the observation that MLL-r AML patients are resistant to chemotherapeutic treatment44, the recipient mice received BM cells from primary MA9-Foxm1fl/fl mice poorly responded to treatment of DOXO and Ara-C (Fig. 5g).